Recent efforts to refine the cell-of-origin and genomic classification for DLBCL subtypes may provide a basis for improved risk stratification and response to new targeted therapies, including MALT1 inhibitors (4–6). Here, MALT1 is linked to diffuse large B-cell lymphoma.